• Grant period: 2024-2027
• Support to the project macrofilaricides for onchocerciasis, phase II
• Total amount: USD 8,187,587
• Link to press release

• Grant period: 2023-2027
• Support to the the project acoziborole for human African trypanosomiasis (HAT)
• Total amount: USD 12,031,712
• Link to press release

• Grant period: 2021-2022
• Support for the assessment of early clinical trial (Phase I) sites capacity
• Total amount: USD 75,377

• Grant period: 2020-2024
• Support to the project macrofilaricides for onchocerciasis
• Total amount: USD 14.254 million plus supplement USD 1,998,271
• Link to press release

• Grant period: 2020-2023
• Support to the project acoziborole for human African trypanosomiasis (HAT)
• Total amount: USD 17.7 million
• Link to press release

• Grant period: 2015-2019
• Portfolio funding for human African trypanosomiasis (HAT), filarial diseases and visceral leishmaniasis
• Total amount: USD 57,527,911
• Link to press release

• Grant period: 2014-2016
• Support to DNDi activities through the “Innovative Fund Award”
• Total amount: USD 1 million

• Grant period: 2011-2015
• Support to screening for neglected tropical diseases
• Total amount: USD 4.3 million

• Grant period: 2011-2015
• Support to the adoption and implementation of new treatment options for visceral leishmaniasis in Asia
• Total amount: USD 7.6 million
• Link to press release

• Grant period: 2011-2014
• Support to the pre-clinical development of a macrofilaricidal drug candidate (flubendazole) for filarial diseases
• Total amount: USD 3.7 million
• Link to press release

• Grant period: 2009-2014
• Support to the clinical development of fexinidazole for human African trypanosomiasis
• Total amount: USD 19.4 million
• Link to press release

• Grant period: 2007-2012
• Support to lead optimization, preclinical, and start of clinical activities for human African trypanosomiasis/visceral leishmaniasis
• Total amount: USD 27.2 million
• Link to press release

• Grant period: 2022-2023
• Support to Hepatitis C PACT
• Total amount: EUR 780,180
• Link to press release

• Grant period: 2017-2020
• Support to hepatitis C
• Total amount: EUR 11,865,103

• Grant period: 2012-2018
• Support to DNDi
• Total amount: USD 7,851,929

• Grant period: 2003-2012
• Support to DNDi
• Total amount: USD 5,912,048

• Grant period: 2011-2012
• Support to the development and registration of the paediatric dosage form of benznidazole for Chagas disease
• Total amount: R$ 1 million

• Grant period: 2024-2025
• Support to DNDi
• Total amount: EUR 4 million

• Grant period: 2019-2023
• Support to DNDi
• Total amount: EUR 20 million

• Grant period: 2014-2018
• Support to DNDi and Global Antibiotic Research and Development Partnership (GARDP) from four Operating Centers: France, Japan, Australia, USA)
• Total amount: EUR 600,000

• Grant period: 2014-2018
• Support to DNDi
• Total amount: EUR 20 million

• Grant period: 2009-2013
• Support to DNDi
• Total amount: EUR 18.4 million

• Grant period: 2003-2008
• Support to DNDi
• Total amount: EUR 25 million
• Link to press release

• Grant period: 2011
• Support to DNDi’s paediatric benznidazole formulation project
• Total amount: EUR 300’000

• Grant period: 2010-2011
• Support to the development and registration of the paediatric dosage form of benznidazole for Chagas disease
• Total amount: EUR 600,000
• Link to press release

• Grant period: 2009
• Support to DNDi malaria project (FACT) – study in Liberia with ASAQ
• Total amount: EUR 100,000
• Link to press release

• Grant period: 2011-2013
• Support to R&D for paediatric HIV programme
• Total amount: EUR 1,135,000

• Grant period: 2010
• Support to R&D opportunities for filarial diseases and paediatric HIV programmes
• Total amount: EUR 165,000

• Grant period: 2009-2012
• Support to DNDi
• Total amount: EUR 400,000

• Support period: 2021-2022
• Collaboration between MSF Switzerland and DNDi
• Total amount: CHF 1,863,288

• Grant period: 2024-2027
• Developing the first innovative treatments against visceral leishmaniasis
• Total amount: GBP 9,055,158

• Grant period: 2022-2023, extended to 2024
• Support to leishmaniasis part 2 (NCE2): 21^st Century treatments for the sustainable elimination of leishmaniasis
• Total amount (including extension): EUR 6,443,330
• Link to press release

• Grant period: 2021-2022
• Support to the development of Target Product Profiles for snake antivenom products
• Total amount: USD 276,768

• Grant period: 2021-2022 (extended to 2023)
• Support to the design and implementation of a translational drug development platform for COVID-19 to generate preclinical evidence in support of treatment arms of the ANTICOV clinical trial
• Total amount GBP 2,444,357 (including 980,066 extension)

• Grant period: 2019-2022
• 21^stCentury treatments for the sustainable elimination of leishmaniasis
• Total amount: EUR 11,357,755
• Link to press release

• Grant period: 2012-2017
• Support to a study to validate PCR and other biomarkers for Chagas disease
• Total amount: USD 3,000,000 + USD 85,182 as supplemental funding + USD 494,631 as additional funding
• Link to press release

• Grant period: 2011-2014
• Support to the Phase II clinical trial of E1224 for Chagas disease
• Total amount: EUR 1,999,801
• Link to press release

• Grant period: 2021-2023
• Moonshot – Development of an investigational new drug from a novel, open-science, orally available small molecule antiviral targeting SARS-CoV-2 main protease
• Total amount: GBP 8 million
• Link to press release

• Grant period: 2018-2019
• Support to the retrospective cohort study on Liposomal amphotericin B as a treatment for VL/HIV co-infected patients in Brazil
• Total amount: R$ 75,000

• Grant period: 2016-2018
• Support to joint DNDi– Epichem Pty Ltd project – Novel compounds for the treatment of leishmaniasis in humans and animals
• Total amount: AUSD 250,000
• Link to announcement

• Grant period: 2016-2018
• Support to DNDi, Lead Optimization Latin America – LOLA, and also to the Chagas Clinical Research Platform and the Network of Investigators and Collaborators in Leishmaniasis – redeLEISH
• Total amount: EUR 4,661,623

• Support period:  2019-2025
• Total amount: BRL 5,587,078
• Support to the FAPESP Consortium to discover new drugs for the treatment of tropical parasitic diseases
• Collaborative funding

• Grant period: 2016-2018
• Support to DNDi, Lead Optimization Latin America – LOLA, and to the Chagas Clinical Research Platform and the Network of Investigators and Collaborators in Leishmaniasis – redLEISH
• Total amount: EUR 100,000

• Support period:  2003-2012
• Support to DNDi
• Collaborative funding

• Through the National Council of Scientific and Technological Development (Conselho Nacional de Desenvolvimento Científico e Tecnológico – CNPq), Brazil
• Grant period: 2020-2023
• Support to phase III studies for new treatments for Chagas and cutaneous leishmaniasis
• Total amount: BRL 3 M (Chagas) and 1.5 M BRL (CL)
• Link to press release

• Grant period: 2013-2015
• Support to DNDi, Chagas disease and leishmaniasis
• Total amount: BRL 995,000 (EUR 324,900)

• Grant period: 2024-2027
• Randomized multicentre Phase II clinical trial conducted in Brazil to evaluate the efficacy, safety, and pharmacokinetics of LXE408 for the treatment of cutaneous leishmaniasis
• Total amount: R$ 9,769,090.53

• Grant period: 2015
• Support to DNDi’s activities through the “Award for Innovation in Social Technology”
• Total amount: EUR 67,000
• Link to press release

• Grant period: 2024-2026
• Improving gender-inclusive treatment access for neglected diseases in LMICs (Chagas/leishmaniasis)
• Total amount: EUR 565,509

• Grant period: 2017-2019
• Support to alliances for Chagas elimination in Central America
• Total amount: CAD 170,000

• Grant period: 2018
• Support to DNDi cutaneous leishmaniasis programme and capacity building in Colombia
• Total amount: USD 501,592

• Grant period: 2015-2016
• Support to DNDi cutaneous leishmaniasis programme (Anfoleish)
• Total amount: USD 317,500 (EUR 269,365)
• Link to press release

• Grant period: 2015-2016
• Support to DNDi cutaneous leishmaniasis programme (Anfoleish) in collaboration with CIDEPRO
• Total amount: COP 762,005,000

• Grant period: 2020-2021
• Support to human African trypanosomiasis case detection and management and community engagement in 14 health zones of the DRC
• Total amount: USD 2.5 million
• Link to press release

EDCTP1 Programme

• Grant period: 2010-2014
• Support to clinical studies for the assessment of the fixed-dose combination of ASMQ as an alternative antimalarial treatment for children in Africa
• Total amount: EUR 577,900

EDCTP2 programme

• Grant period: 2021-2024
• Support to the project LeishAccess (African leishmaniasis: From clinical research to access)
• Total amount: EUR 4.3 million

• Grant period: 2021-2024
• Support to the development of next generation diagnostics and oral treatment for visceral leishmaniasis in Eastern Africa (VL-Inno)
• Total amount: EUR 4,970,462

• Grant period: 2020-2025
• Development of a paediatric indication for children for a safe, effective, all-oral single-dose treatment formulation of acoziborole for HAT (ACOZI-KIDS)
• Total amount: EUR 3 million

• Grant period: 2020-2024
• Development of an improved flucytosine formulation for the treatment of cryptococcal meningitis in advanced HIV disease
• Total amount: EUR 3.7 million

• Grant period: 2020-2024
• Support to capacity development to facilitate the delivery and uptake of fexinidazole for the elimination of HAT
• Total amount: EUR 2.5 million

• Grant period: 2020
• Support to the preparatory activities for ANTICOV clinical study for COVID-19
• Total amount: EUR 200,000

• Grant period: 2018-2023
• Support to HAT-r-ACC, towards an arsenic-free oral treatment
• Total amount: EUR 3,769,845*
• *Includes EUR 125,000 granted by the Fundação para Ciência e a Tecnologia (FCT), Portugal (www.fct.pt)

• Grant period: 2017-2020
• Support to Afri-KA-DIA, towards an adapted, safe, effective combination treatment for African visceral leishmaniasis and improved diagnostic tools
• Total amount: EUR 5,560,784
• Link to press release
• www.afrikadia.org

• Grant period: 2002-2008
• Support to DNDi malaria project (FACT)
• Total amount: EUR 146,825
• cordis.europa.eu/inco/

• Grant period: 2006-2009
• Support for Clinical Trial Capacity Platform for sleeping sickness in Africa
• Total amount: EUR 340,000

• Grant period: 2013-2016
• Support to AfriCoLeish – Development of a care package for treatment and control of visceral leishmaniasis in East Africa
• Total amount: EUR 6 million
• Link to initial press release
• www.africoleish.org
• cordis.europa.eu/projects/

• Grant period: 2009-2012
• Support to LEISHDNAVAX – Development of a DNA vaccine for visceral leishmaniasis
• Total amount: EUR 253,800
• ec.europa.eu/research/health/

• Grant period: 2019-2024
• Support to the filarial disease programme
• Total amount: EUR 2,280,000
• Helminth Elimination Platform (HELP)

• Grant period: 2022-2025
• Ending COVID-19 variants of concern through cohort studies (END-VOC): support biobanking and sequencing capacity for ANTICOV to enable the assessment of current and emerging variants and their transmission rate.
• Total amount: EUR 448,750

• Grant period: 2019-2022
• Develop work carried out on the innovative DNDi model through the lens of the “commons”, introduce new drugs for sleeping sickness and provide HIV-positive newborns and very young children with an optimal antiretroviral drug
• Total amount: EUR 8 million
• Link to press release

• Grant period: 2015-2018
• Support to specific projects on visceral leishmaniasis in Africa
• Total amount: EUR 2 million
• Link to press release

• Grant period: 2012-2017
• Support to specific projects in Africa: technology transfer of ASAQ for Malaria, clinical trials for ASMQ (Malaria), development of a new oral treatment for human African trypanosomiasis (HAT), support to the HAT Platform and development of a new paediatric formulation of HIV
• Total amount: EUR 5 million

• Grant period: 2006-2010
• Support to DNDi malaria project (FACT)
• Total amount: EUR 2 million
• Link to initial press release

• Grant period: 2009-2011
• Support to specific discovery and lead optimisation projects for human African trypanosomiasis, Chagas disease, and leishmaniasis
• Total amount: EUR 1.3 million

• Grant period: 2007-2010
• Support DNDi’s disease programmes for human African trypanosomiasis and visceral leishmaniasis in Africa (preclinical, clinical and implementation activities and capacity building.)
• Total amount: EUR 5.9 million

• Grant period: 2022-2024
• Support to the DZIF member and associated institutions : Heidelberg University, Philipps-Universität Marburg, Charité – Universitätsmedizin Berlin, University of Bonn, University of Hamburg, Justus Liebig University Giessen, the Helmholtz Centre for Infection Research and the Bernhard Nocht Institute for Tropical Medicine, for the “Nucleoside booster” project.
• Total amount: EUR 784,200

• Grant period: 2023-2028
• Support to the facilitation of access to treatments and diagnostics for Poverty Related and Neglected Diseases (PRNDs)
• Total amount: EUR 20 million
• Link to press release
• Link to factsheet on Germany’s contribution for DNDi’s work (in German)

• Grant period: 2018-2019
• Support to Global Antibiotic Research & Development Partnership (GARDP)
• Total amount: EUR 10.8 million

• Grant period: 2018-2019
• Support to Global Antibiotic Research & Development Partnership (GARDP)
• Total amount: EUR 14.7 million

• Grant period: 2018-2019
• Support to Global Antibiotic Research & Development Partnership (GARDP)
• Total amount: EUR 10 million

• Grant period: 2018-2019
• Support to Global Antibiotic Research & Development Partnership (GARDP)
• Total amount: EUR 14.5 million

• Grant period: 2023-2028
• Support to the development of products for the prevention, diagnosis and treatment of poverty-related neglected diseases
• Total amount awarded : EUR 10 million
• Link to press release
• Link to factsheet on Germany’s contribution for DNDi’s work (in German)

• Grant period: 2016-2021 (extended to 2023 through additional fundings)
• Support to DNDi’s development of products for the prevention, diagnosis and treatment of neglected and poverty-related diseases
• Total amount awarded in 2016: EUR 10 million
• Additional EUR 15 million for COVID-19 activities in resource limited settings granted for 2020-2022
• Additional EUR 4.5 million for development of treatments for neglected and poverty-related diseases, 2021-2022
• Additional EUR 2.45 for the PANdemic preparedness plaTform for Health and Emerging infections’ Response (PANTHER)
• Link to press releases: November 2016 / January 2022
• Link to factsheet on Germany’s contribution for DNDi’s work (in German)

• Grant period: 2011-2015
• Support to DNDi’s disease programmes for human African trypanosomiasis, Chagas disease, leishmaniasis and filarial diseases (from screening to clinical studies for new and improved products as well as capacity strengthening activities through the disease platforms)
• Total amount: EUR 9.1 million (including supplemental of EUR 1.1 million for 2015) Link to press release

• Grant period: 2018-2019
• Support to Global Antibiotic Research & Development Partnership (GARDP)
• Total amount: EUR 500,000

• Grant period: 2018-2019
• Support to Global Antibiotic Research & Development Partnership (GARDP)
• Total amount: EUR 1 million

• Grant period: 2017-2018
• Support to Global Antibiotic Research and Development Partnership (GARDP)
• Total amount: EUR 1,350,000

• Grant period: 2017
• Support to Global Antibiotic Research and Development Partnership (GARDP)
• Total amount: EUR 750,000

• Grant period: 2016-2017
• Support to Global Antibiotic Research and Development Partnership (GARDP)
• Total amount: EUR 500,000
• Link to press release

• Grant period: 2008-2009
• Support to specific discovery, preclinical/clinical projects (screening, lead optimization for Chagas disease, Fexinidazole for human African trypanosomiasis)
• Total amount: EUR 1 million

• Grant period: 2017-2018
• Support to the leishmaniasis global R&D and access initiative-Phase 2
• Total amount: USD 335,000

• Grant period: 2015-2017
• Support to the DNDi’s Demonstration Projects on leishmaniasis (VL; CL)
• Total amount: EUR 2.3 million
• Link to press release

• Grant period: 2007-2008
• Support to the development of SSG&PM (Paromomycin project) and capacity strengthening for visceral leishmaniasis
• Total amount: EUR 200,000

• Grant period: 2024-2026
• Support to the lead optimization of a novel candidate series for Chagas disease
• Total amount: JPY 294,532,531
• Link to press release

• Grant period: 2023-2025
• Support to the registration of fosravuconazole for eumycetoma and preparatory activities needed to facilitate patients’ access
• Total amount: JPY 296,466,665
• Link to press release

• Grant period: 2023-2024
• Support to the screening project with Nagasaki University for Chagas disease
• Total amount: DNDi’s contribution to be provided fully on an in-kind basis
• Link to press release

• Grant period: 2023-2024
• Support to the Preclinical development of CC-6166, a selective macrofilaricide for the treatment of river blindness
• Total amount: JPY 30,000,000 (to conduct non-GLP toxicology studies)
• Link to press release

• Grant period: 2021-2023
• Support to the target research “autophagy as a novel drug-development target for Chagas disease”
• Total amount: JPY 98,920,080
• Link to press release

• Grant period: 2021-2023
• Support to the screening project with Daiichi Sankyo Company Limited
• Total amount: JPY 10,976,301 and supplemental JPY 3,618,035
• Link to press release

• Grant period: 2021-2023
• Support to the screening project with Takeda Pharmaceutical Company Ltd.
• Total amount: JPY 8,994,695 and supplemental JPY 5,440,211
• Link to press release

• Grant period: 2021-2023
• Support to the screening project with The University of Tokyo for visceral leishmaniasis
• Total amount: supplemental JPY 5,421,000
• Link to press release

• Grant period: 2021-2023
• Support to the lead optimization and preclinical candidate selection from the NTD Drug Discovery Booster series for visceral leishmaniasis
• Total amount: JPY 225,744,281
• Link to press release

• Grant period: 2021-2023
• Support to the preclinical development of DNDI-6174 a drug candidate for leishmaniasis
• Total amount: JPY 612,293,801 + supplemental JPY 112,010,934
• Link to press release

• Grant period: 2021-2023
• Support to the project “Hit-to-lead development for neglected tropical diseases” with Mitsubishi Tanabe
• Total amount: JPY 117,066,370 + supplemental JPY 9,741,243
• Link to press release

• Grant period: 2020-2024
• Support to the clinical development of CpG D35 for combined treatment of cutaneous leishmaniasis
• Total amount: JPY 692,399,748 and supplemental JPY 28,116,031 + JPY 31,792,205
• Link to press release

• Grant period: 2020-2021
• Support to screening activities for Natural Products
• Total amount: JPY 8,000,000

• Grant period: 2020-2022
• Support to lead optimization of candidates for Chagas disease with Daiichi Sankyo
• Total amount: JPY 431,856,560
• Link to announcement

• Grant period: 2019-2020
• Support to identify progressable hit series against Leishmania donovani and T. cruzi
• Total amount: JPY 15,000,000
• Link to press release

• Grant period: 2018-2020
• Support to preclinical development and phase I activities on a selected aminopyrazole compound for visceral leishmaniasis
• Total amount: JPY 604,775,700
• Link to press release

• Grant period: 2018-2020
• Support to screening activities for Natural Products
• Total amount: JPY 11,900,000
• Link to announcement

• Grant period: 2018-2020
• Support to NTD Drug Discovery Booster III
• Total amount: JPY 149,832,868

• Grant period: 2017-2023
• Support to mycetoma treatment, fosravuconazole clinical trial
• Total amount: JPY 252,621,720 and JPY 26,048,320 supplemental
• Link to announcement

• Grant period: 2017-2019
• Support to target bromodomains for novel anti-parasitic mechanisms of action for malaria, Chagas disease, leishmaniasis, and cryptosporidiosis
• DNDi’s contribution to be provided fully on an in-kind basis
• Link to announcement

• Grant period: 2017-2020
• Support to DNDi preclinical development of CpG D35 for combined treatment of cutaneous leishmaniasis
• Total amount: JPY 491,867,214
• Link to announcement

• Grant period: 2017-2018
• Support to the Drug Discovery Booster II
• Total amount: JPY 54,944,748
• Link to announcement

• Grant period: 2017-2020
• Support for identification of lead compounds for visceral leishmaniasis and Chagas disease
• Total amount: JPY 78,000,000 and JPY 40,000,000 supplemental
• Link to announcement and press release

• Grant period: 2016-2020
• Support to screening activities
• Total amount: JPY 3,100,000

• Grant period: 2016-2018
• Support to screening activities
• Total amount: JPY 21,050,000

• Grant period: 2016-2017
• Support to DNDi preclinical efficacy of CpG D35 combination therapy for treatment of complicated cutaneous leishmaniasis
• Total amount: JPY 68,771,551
• Link to announcement

• Grant period: 2015-2017
• Support to lead optimization for visceral leishmaniasis
• Total amount: JPY 402,255,299
• Link to announcement

• Grant period: 2015-2017
• Support to the Drug Discovery Booster
• Total amount: JPY 79,543,796
• Link to press release

• Grant period: 2014-2019
• Support to DNDi Chagas disease programme (E1224 combination study & benznidazole)
• Total amount: JPY 384,089,264

• Grant period: 2013-2018
• Support to screening activities
• Total amount: JPY 15,872,200

• Grant period: 2017-2018
• Support to Global Antibiotic Research and Development Partnership (GARDP)
• Total amount: EUR 100,000
• Link to press release

• Support period: 2016-2018
• Support to DNDi
• Collaborative funding

• Grant period: 2022-2024
• Support to improving access to available innovative HIV paediatric treatments for ending the neglect of HIV-infected children
• Total amount: EUR 300,000
• Link to press release

• Grant period: 2013-2017
• Support to DNDi’s disease programme for human African trypanosomiasis
• Total amount: NOK 22 million
• Link to press release

• Grant period: 2023-2024
• 2022 Norwegian TV-Aksjonen attributed to DNDi to support leishmaniasis and sleeping sickness activities (R&D and access)
• Total amount: NOK 50 million
• Link to news

• Support to HAT-r-ACC through EDCTP2
• Total amount : EUR 125,000

• Grant period: 2022-2023
• Support to low-cost manufacturing of DNDI-6148 for visceral leishmaniasis
• Total amount: KRW 470’339’900
• Link to press release

• Grant period: 2021
• Africa Rapid Grant Fund to support ANTICOV Science Engagement Project (ASEC)
• Total amount: USD 20,000

• Grant period: 2017-2019
• Support to Global Antibiotic Research and Development Partnership (GARDP)
• Total amount: R 10,000,000
• Link to press releases: May 2016/ September 2017 

• Grant period: 2024-2026
• Strengthen the monitoring and evaluation of neglected diseases in Bolivia to support the health system and have updated information on public health needs
• Total amount: EUR 139,500
• Funding received through Fundación SANIT (Bolivia)

• Grant period: 2007-2012
• Support to DNDi
• Total amount: EUR 12 million

• Grant period: 2017-2019
• Support to Global Antibiotic Research and Development Partnership (GARDP)
• Total amount: CHF 500,000
• Link to press release

• Grant period: 2016-2017
• Support to Global Antibiotic Research and Development Partnership (GARDP)
• Total amount: CHF 360,000
• Link to press release

• Grant period: 2018-2020
• Support for simplification and decentralization of HCV testing and treatment in Malaysia
• Total amount: 924,580 USD (Supported by Unitaid unitaid.eu)

• Grant period: 2019-2021
• Support to the University of Geneva for the project “Development of waltherione F-based chemical entities for Chagas disease”
• Total amount: CHF 276,000

• Grant period: 2024
• Support to the Innovation for Children programme
• Total amount: CHF 22,000

• Grant period: 2023
• Support to the Innovation for Children programme
• Total amount: CHF 32,000

• Grant period: 2022-2024
• Second support to mycetoma to corroborate results of fosravuconazole and prepare access in Sudan
• Total amount: CHF 550,000
• Link to press release

• Grant period: 2020-2021
• Support to COVID-19 Clinical Research Coalition
• Total amount: CHF 50,000

• Grant period: 2019-2021
• Support to mycetoma activities in Sudan
• Total amount: CHF 600,000
• Link to press release

• Grant period: 2016-2018
• Support to HAT (human African trypanosomiasis) activities
• Total amount: CHF 480,000

• Grant period: 2013-2015
• Support to  HAT (human African trypanosomiasis) activities
• Total amount: CHF 500,000

• Grant period: 2010-2012
• Support to the implementation of NECT (NECT-Field project) for human African trypanosomiasis
• Total amount: CHF 600,000

• Grant period: 2004-2009
• Support to the development of SSG&PM (paromomycin project) for visceral leishmaniasis
• Total amount: CHF 1 million

• Grant period: 2021-2024
• Support to develop lifesaving medicines for people with neglected diseases around the world
• Total amount: CHF 8 million
• Link to press release

• Grant period: 2019
• Support to the project “Towards an innovative single dose oral treatment for Human African Trypanosomiasis”
• Total amount: CHF 1,315,520

• Grant period: 2017-2020
• Support to DNDi
• Total amount: CHF 8 million

• Grant period: 2017-2018
• Support to an innovative oral combination treatment for visceral leishmaniasis
• Total amount: CHF 500,000

• Grant period: 2013-2016
• Support to DNDi
• Total amount: CHF 8 million
• Link to press release

• Grant period: 2012-2013
• Support to DNDi Malaria programme
• Total amount: CHF 900,000

• Grant period: 2010-2012
• Support to DNDi
• Total amount: CHF 4 million
• Link to press release

• Grant period: 2005-2006
• Support to DNDi Malaria programme
• Total amount: CHF 120,000

• Grant period: 2023-2028
• Grant name: Stop Transmission of gambiense Human African Trypanosomiasis (STROGHAT)
• Total amount: EUR 1,535,768 (for DNDi)

• Grant period: 2023-2028
• Support to establish for the first time in NTDs, an adaptive clinical trial platform and improve clinical research infrastructure for four Sub Saharan countries (eWHORM)
• Total amount: EUR 1,808,465 (for DNDi)
• Link to press release

• Grant period: 2010-2012
• Support to the baseline and endpoint survey work for the independent evaluation of phase 1 of the Affordable Medicines Facility – malaria (AMFm) in Ghana
• Total amount: EUR 0.5 million

• Grant period: 2024-2027
• Support to the death prevention among adults and children by simplifying Advanced HIV disease management
• Total amount: USD 2.038 million

• Grant period: 2020-2022
• Support to the ANTICOV clinical study for COVID-19
• Total amount: USD 14.7 million

• Grant period: 2020
• Support to the preparation of the ANTICOV study for COVID-19
• Total amount: EUR 380,000

• Grant period: 2013-2017
• Support to the development of child-adapted antiretroviral (ARV) formulation
• Total amount: USD 17.3 million
• Link to press release

• Support period: 2017
• Support to DNDi
• Collaborative funding

• Grant period: 2022-2027
• Support DNDi to develop and facilitate access to products intended to promote sexual and reproductive health and combat poverty-related diseases
• Total amount: EUR 14 million
• Link to press release

• Grant period: 2015-2021
• Support to DNDi’s disease programmes for human African trypanosomiasis (HAT), Chagas disease, leishmaniasis and mycetoma (from screening to clinical studies and implementation for new and improved products).
• Total amount: EUR 19.2 million (including 3.2 million extension for 2021)

• Grant period: 2011-2014
• Support to DNDi’s disease programmes for human African trypanosomiasis (HAT), Chagas disease, and leishmaniasis (from screening to clinical studies and implementation for new and improved products).
• Total amount: EUR 14 million
• Link to press release

• Grant period: 2006-2010
• Support to DNDi malaria project (FACT)
• Total amount: EUR 2.9 million

• Grant period: 2017-2018
• Support to Global Antibiotic Research and Development Partnership (GARDP)
• Total amount: EUR 2.5 million
• Link to press releases: May 2016 / September 2017 

• Grant period: 2018-2019
• Support to Global Antibiotic Research & Development Partnership (GARDP)
• Total amount: GBP 1 million

• Grant period: 2021-2023
• ANTICOV India – Testing multiple early treatment options for mild COVID- 19 infected patients in India
• Total amount: GBP 3.8 million

• Grant period: 2017-2021 (extended to 2023 and then 2024)
• Support to DNDi and GARDP
• Total amount: GBP 50 million (including 2 million for GARDP)
• Additional funding for 2019-2021: GBP 10 million
• Additional funding for 2021-2022: GBP 5.3 million
• Additional funding for 2023-2024: GBP 6 million

• Grant period: 2018
• Support to DNDi
• Total amount: GBP 4 million

• Grant period: 2017
• Support to DNDi
• Total amount: GBP 4.05 million

• Grant period: 2015
• Support to DNDi
• Total amount: GBP 3 million

• Grant period: 2014
• Support to DNDi
• Total amount: GBP 3 million

• Grant period: 2013-2018
• Support to DNDi
• Total amount: GBP 30 million
• Link to press release

• Grant period: 2009-2013
• Support to DNDi
• Total amount: GBP 24.9 million
• Link to press release

• Grant period: 2006-2008
• Support to DNDi
• Total amount: GBP 6.5 million
• Link to press release

• Grant period: 2022-2024
• Total amount: USD 2,624,853
• Support to AI-driven Structure-enabled Antiviral Platform (ASAP)
• Link to press release

• Grant period: 2010-2013
• Support to preclinical activities (K777 project) for Chagas disease
• Total amount: USD 1.2 million

• Grant period: 2007-2012
• Support to Amphotericin B Polymer project for visceral leishmaniasis
• Total amount: USD 1.5 million
• Link to press release

• Grant period: 2014-2019
• Support to the DNDi’s portfolio on filarial diseases
• Total amount: USD 10 million
• Link to press release

• Grant period: 2011
•  Support to the DNDi’s communication toolbox to inform populations on available benznidazole pediatric treatment in Chagas-endemic countries
• Total amount: USD 50,000